Okimoto Niro, Kibayashi Takashi, Mimura Kimihiro, Yamato Kenji, Kurihara Takeyuki, Honda Yoshihiro, Osaki Kohichi, Asaoka Naoko, Ohba Hideo
Center of Respiratory Diseases, Kawasaki Medical School Kawasaki Hospital, 2-1-80 Nakasange, Okayama 700-8505, Japan.
J Infect Chemother. 2005 Dec;11(6):274-7. doi: 10.1007/s10156-005-0410-2.
The clinical effect of gatifloxacin (GFLX) at 200 mg daily (half of common dosage) on bacterial community-acquired pneumonia in the elderly was examined. Subjects were 30 patients with bacterial community-acquired pneumonia aged 65 years or more (mild, 21 patients; moderate, 9 patients), and GFLX at 100 mg per dose was administered twice daily for 4-14 days. The results included clinical effectiveness in 21 of 21 mildly affected patients (efficacy rate, 100%), in 8 of 9 moderately affected patients (efficacy rate, 88.9%), and 29 of a total of 30 patients (efficacy rate, 96.7%). With regard to bacteriological effect, 28 of 29 strains were eradicated (eradication rate, 96.6%). Abnormal laboratory findings included mild elevations in GPT, GOT, and ALP in only 1 patient. Based on these findings, we concluded that administration of GFLX at 200 mg daily is recommended for bacterial community-acquired pneumonia in the elderly.
研究了加替沙星（GFLX）每日200mg（常规剂量的一半）对老年细菌性社区获得性肺炎的临床疗效。研究对象为30例65岁及以上的细菌性社区获得性肺炎患者（轻度21例，中度9例），给予GFLX每剂量100mg，每日两次，持续4 - 14天。结果显示，21例轻度患者中有21例临床有效（有效率100%），9例中度患者中有8例有效（有效率88.9%），30例患者中共有29例有效（有效率96.7%）。在细菌学疗效方面，29株菌株中有28株被清除（清除率96.6%）。实验室检查异常仅1例患者出现GPT、GOT和ALP轻度升高。基于这些结果，我们得出结论，对于老年细菌性社区获得性肺炎，推荐每日给予200mg加替沙星。
Zotero 插件